Intelligence · Clinical pipeline
Oncology · Phase II
Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.
Quick answer
Oncology Phase II programs: NovaPharmaNews indexes 2,637 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.
Top sponsors
- First People's Hospital 261 programs
- Chinese Academy of 198 programs
- George Institute for 118 programs
- United Therapeutics Europe 112 programs
- Telethon Foundation 91 programs
- Takeda 79 programs
- Regeneron UK 71 programs
- MSD Merck Sharp 63 programs
- Ningbo Cancer Hospital 62 programs
- Anaxis Pharma 57 programs
- AstraZeneca 52 programs
- HOFFMANN-LA ROCHE 50 programs
Pipeline programs
-
D8530C00002
AstraZeneca AB
Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer
1 trial -
D9077C00001
AstraZeneca AB
Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer
1 trial -
D9102C00001
AstraZeneca AB
Stage IV Non Small Cell Lung Cancer whose tumors lack EGFR mutations and ALK fusions
1 trial -
D9106C00002
AstraZeneca AB
Non-small Cell Lung Cancer (NSCLC)
1 trial -
D933LC00001
AstraZeneca AB
First-line (1L) Stage IV Triple Negative Breast Cancer (TNBC) - the subtype of breast cancer characterized by a lack of tumor expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2.
1 trial -
D9520C00001
AstraZeneca AB
Metastatic Prostate Cancer
1 trial -
D9571C00001
AstraZeneca AB
Relapsed/Refractory Classical Hodgkin Lymphoma
1 trial -
D967LC00001
AstraZeneca AB
Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-expressing gastric, GEJ and esophageal cancer
1 trial -
D9720C00001
AstraZeneca AB
Advanced Solid Tumors
1 trial -
D9720C00003
AstraZeneca AB
Metastatic Prostate Cancer
1 trial -
D9804C00001
AstraZeneca AB
Locally Advanced Resectable Gastroesophageal Adenocarcinoma
1 trial -
DABRAFENIB , TRAMETINIB
Disc Medicine
ANAPLASTIC THYROID CANCER
1 trial -
DARATUMUMAB for Relapsed or Refractory Plasmablastic lymphoma
Fondazione Telethon ETS
Relapsed or Refractory Plasmablastic lymphoma
1 trial -
DAROTAXEL
Disc Medicine
metastatic castration-resistant prostate cancer
1 trial -
DC-CIK Immunotherapy
The First People's Hospital of Lianyungang
Breast Cancer
1 trial -
DC-VACCINE_IRSTIRCCS for Stage IV colorectal cancer
Istituto Gentili S.r.l.
Stage IV colorectal cancer
1 trial -
DC1 Vaccine
United Therapeutics Europe Ltd
Breast Cancer Female
1 trial -
DCC-3014-01-001
Lacuna Pharma Pty Ltd
Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor
1 trial -
DCC-3084, DCC-3084
Lacuna Pharma Pty Ltd
Solid tumors driven by the MAPK Pathway
1 trial -
DCC-3116-01-001
Lacuna Pharma Pty Ltd
Non-Small Cell Lung Cancer, Metastatic Solid Tumor, Advanced Solid Tumor
1 trial -
DCVax-Direct
NORTHWEST BIOTHERAPEUTICS INC
Locally Advanced Tumor
1 trial -
DCVax-L and T Cells
NORTHWEST BIOTHERAPEUTICS INC
Ovarian Cancer
1 trial -
DEB-TACE+HAIC
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hepatocellular Carcinoma Non-resectable
1 trial -
DESTINY-Breast07
AstraZeneca AB
HER2-positive Metastatic Breast Cancer
1 trial -
DS-1062a
Daiichi Sankyo
Non-small Cell Lung Cancer
1 trial -
DS-3939a
Daiichi Sankyo
Metastatic Solid Tumor, Advanced Solid Tumor
1 trial -
DS-8201a
Daiichi Sankyo
Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (IHC) 0 Breast Cancer
1 trial -
DS-8201a
AstraZeneca AB
HER2 Expressing Tumors
1 trial -
DS-8201a
AstraZeneca AB
Treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless of tumor histology
1 trial -
DS-8201a
Ningbo Cancer Hospital
Metastatic Breast Cancer HR+, HER2-
1 trial -
DS3201-330
Daiichi Sankyo
Advanced or Metastatic Non-Small Cell Lung Cancer
1 trial -
DS7300-189
Daiichi Sankyo
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
1 trial -
DSC/11/2357/44
Italfarmaco S.p.A.
Chronic myeloproliferative neoplasm
1 trial -
DURVALUMAB
Fondazione Telethon ETS
Non Small Cell Lung Cancer
1 trial -
DYP688
Novartis Pharmaceuticals
Metastatic uveal melanoma, other GNAQ/11 mutant melanomas (e.g. skin or mucosal melanoma)
1 trial -
Dabogratinib (TYRA-300) 60mg
Tyra Biosciences
Low Grade Upper Tract Urothelial Carcinoma
1 trial -
Dabrafenib
Novartis Pharmaceuticals
Cancer
1 trial -
Dalpiciclib
The First People's Hospital of Lianyungang
Early Breast Cancer
1 trial -
Danggui Buxue Tang
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
1 trial -
Daraxonrasib
Revolution Medicines
Advanced Solid Tumors
1 trial -
Darinaparsin
Alaunos Therapeutics
HEPATOCELLULAR CARCINOMA
1 trial -
Darinaparsin
Alaunos Therapeutics
Hematologic Neoplasms
1 trial -
Darleukin, Fibromun
Philogen S.p.A.
locally advanced basal cell carcinoma patients
1 trial -
Darleukin, Fibromun
Philogen S.p.A.
Patients with high-risk, locally advanced (non-metastatic, node negative, single or multifocal), Basal Cell Carcinoma (BCC) or cutaneous Squamous Cell Carcinoma (cSCC) amenable to intratumoral injection, not eligible to surgery or radiation therapy according to the evaluation of a local interdisciplinary tumor board or who refuse surgery or radiation therapy and for whom a histological evaluation is available according to international guidelines.
1 trial -
Darolutamide+ADT
The First People's Hospital of Lianyungang
Prostate Cancer
1 trial -
Darovasertib
Hospital Authority, Hong Kong
Ocular Melanoma
1 trial -
Dasatinib
Bristol-Myers Squibb
Chronic Myeloid Leukemia
1 trial -
Dasatinib
Takeda
Acute Lymphoblastic Leukemia
1 trial
Frequently asked questions
How many oncology Phase II programs exist?
2,637 programs match both the therapeutic area and stage filters in our published index.